Amgen Inc.

The filings describe rising earnings alongside rising pressure on the balance sheet. The Altman Z″-Score of 0.14 falls in the distress zone, the label's range below 1.10. In plain English, this model combines working capital, retained earnings, operating profit, equity value and sales into one number; a low figure means the balance sheet looks weak relative to liabilities. The model is not designed for banks or financial firms, and Amgen is a drug manufacturer, so the score applies here, but it still needs context. A distress-zone reading does not mean near-term failure, since Amgen reported $9.96 billion of operating cash flow in 2025, but it signals that leverage deserves a close read. The operating cash flow to net income ratio of 1.29 means operating cash flow was about 29% above reported net income in 2025. That ratio was about 2.81 in 2024, computed from $11.49 billion and $4.09 billion, and it fell because net income rose faster than operating cash flow declined. This is a meaningful shift in earnings quality that readers may want to look at alongside the other income line. The Beneish M-Score, Piotroski F-Score and Fog Index are not on file for this filing, so this synthesis does not characterize them. Revenue growth of 10.0% is the most direct growth measure available. Filing items readers may want to look at include the July 31, 2025 MFN Letter, the July Tariff EOs effective August 7, 2025, the One Big Beautiful Bill Act signed July 4, 2025, the Inflation Reduction Act, the biosimilar competition risk factor cross-referenced in the MD&A, and the orphan drug exclusivity held for BLINCYTO and UPLIZNA. The risk-factor excerpt provided for the 10-Q is a table of contents, so the detailed risk text was not available for this review. No news items were on file.

Catalyst.Amgen's revenue rose to $36.75 billion in 2025 from $33.42 billion in 2024, a 10.0% increase, and net income climbed to $7.71 billion from $4.09 billion. The 10-Q income statement shows the growth coming from product sales: third-quarter 2025 product sales were $9,137 million versus $8,151 million a year earlier, and nine-month total revenues reached $26,885 million against $24,338 million. Management is also spending more on research, with nine-month R&D expense of $5,130 million versus $4,240 million. The filings name Repatha, Prolia, XGEVA and MariTide among the products and product candidates.

Hidden risk.The Altman Z″-Score for 2025 is 0.14, which falls in the distress zone (below 1.10). This is a statistical screen rather than a forecast of default, but it reflects a thin equity base against a large debt load: long-term debt was $50.01 billion at year-end 2025 against equity of $8.66 billion. Operating cash flow also fell to $9.96 billion from $11.49 billion even as net income rose. The 10-Q shows other income, net of $3,204 million for the first nine months of 2025 versus $1,288 million a year earlier, and 'Other' operating expenses of $1,236 million versus $187 million. Readers may want to look at what drove the net income gain.